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Increased susceptibility for intrahepatic cholestasis of pregnancy
and contraceptive-induced cholestasis in carriers of the 1331T>C
polymorphism in the bile salt export pump
Abstract
AIM: To study the association of three common ABCB11 and ABCC2 polymorphisms (ABCB11:
1331T>C --> V444A; ABCC2: 3563T>A --> V1188E and 4544G>A --> C1515Y) with intrahepatic
cholestasis of pregnancy (ICP) and contraceptive-induced cholestasis (CIC). METHODS: ABCB11 and
ABCC2 genotyping data were available from four CIC patients and from 42 and 33 ICP patients,
respectively. Allele-frequencies of the studied polymorphisms were compared with those in healthy
pregnant controls and Caucasian individuals. Furthermore, serum bile acid levels were correlated with
the presence or absence of the 1331 C allele. RESULTS: The ABCB11 1331T>C polymorphism was
significantly more frequent in cholestatic patients than in pregnant controls: C allele 76.2% (CI,
58.0-94.4) vs 51.3% (CI 35.8-66.7), respectively (P = 0.0007); and CC allele 57.1% (CI 36.0-78.3) vs
20% (CI 7.6-32.4), respectively (P = 0.0065). All four CIC patients were homozygous carriers of the C
allele. In contrast, none of the studied ABCC2 polymorphism was overrepresented in ICP or CIC
patients. Higher serum bile acid levels were found in carriers of the 1331CC genotype compared to
carriers of the TT genotype. CONCLUSION: Our data support a role for the ABCB11 1331T>C
polymorphism as a susceptibility factor for the development of estrogen-induced cholestasis, whereas no
such association was found for ABCC2. Serum bile acid and gamma-glutamyl transferase levels might
help to distinguish ABCB4- and ABCB11-related forms of ICP and CIC.
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Abstract 
AIM: The bile salt export pump (BSEP, ABCB11) and the multidrug resistance protein 2 (MRP2, 
ABCC2) might be of pathogenetic importance in intrahepatic cholestasis of pregnancy (ICP) and 
contraceptive-induced cholestasis (CIC). We therefore studied the association of three common 
ABCB11 and ABCC2 polymorphisms (ABCB11: 1331T>C → V444A; ABCC2: 3563T>A → V1188E 
and 4544G>A → C1515Y) with ICP and CIC.  
METHODS: ABCB11 and ABCC2 genotyping data were available from four CIC patients and 
from 42 and 33 ICP patients, respectively. Allele-frequencies of the studied polymorphisms were 
compared with those in healthy pregnant controls and Caucasian individuals. Furthermore, 
serum bile acid levels were correlated with the presence or absence of the 1331 C allele. 
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RESULTS: The ABCB11 1331T>C polymorphism was significantly more frequent in cholestatic 
patients than in pregnant controls: C allele 76.2% (CI, 58.0–94.4) vs 51.3% (CI 35.8–66.7), 
respectively (P = 0.0007); and CC allele 57.1% (CI 36.0–78.3) vs 20% (CI 7.6–32.4), 
respectively (P = 0.0065). All four CIC patients were homozygous carriers of the C allele. In 
contrast, none of the studied ABCC2 polymorphism was overrepresented in ICP or CIC patients. 
Higher serum bile acid levels were found in carriers of the 1331CC genotype compared to 
carriers of the TT genotype. 
CONCLUSION: Our data support a role for the ABCB11 1331T>C polymorphism as a 
susceptibility factor for the development of estrogen-induced cholestasis, whereas no such 
association was found for ABCC2. Serum bile acid and γ-glutamyl transferase levels might help 
to distinguish ABCB4- and ABCB11-related forms of ICP and CIC. 
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INTRODUCTION 
Intrahepatic cholestasis of pregnancy (ICP) and oral contraceptive-induced cholestasis (CIC) are 
two acquired forms of cholestasis, which are observed in otherwise healthy young women with 
a normal medical history. Both syndromes are rapidly reversible upon discontinuation of the 
hormonal challenge, i.e. after delivery or cessation of the causative drug, which suggests that 
female sex hormones play a key pathogenic role in these forms of cholestasis[1,2]. In line with 
these observations, ICP usually occurs during the third trimester of pregnancy, when serum 
concentrations of estrogens and progesterone reach their peak[3,4]. Furthermore, women with 
ICP and female family members of ICP patients have an increased susceptibility to develop 
intrahepatic cholestasis under oral contraception[5]. 
A genetic predisposition for both types of hormonal cholestasis has been suspected 
based upon the strong regional clustering[6], the higher prevalence in female family members of 
patients with ICP[5,7] and the co-incidence with hereditary cases of progressive familial 
intrahepatic cholestasis[5,7]. Recently, mutations in the ABCB4 gene that encodes the canalicular 
phospholipid flippase multidrug resistance protein 3 (MDR3) have been implicated in the 
development of ICP and CIC in a subset of affected patients[5,8–12]. MDR3-associated cases of 
hormonal cholestasis are associated with elevated serum γ-glutamyl transferase (γ-GT) levels in 
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80% of affected patients, which reflects cholangiocytic damage characteristic of MDR3 
dysfunction[11].  
In the same study, the majority of ICP women without ABCB4 mutations exhibited 
normal γ-GT levels[11], which suggests a different pathogenic mechanism in this subset of 
patients. Dysfunction of the bile salt export pump (BSEP) or the multidrug resistance associated 
protein 2 (MRP2) have therefore been proposed as alternative candidate proteins involved in 
the pathogenesis of hormonal cholestasis. BSEP constitutes the predominant bile salt efflux 
system of hepatocytes, which mediates the cellular excretion of numerous conjugated bile salts 
into the bile canaliculus[13–16]. In contrast, the bilirubin transporter MRP2 is the main driving 
force for bile-salt-independent bile flow through canalicular excretion of reduced 
glutathione[17,18]. Given their important roles in bile formation and bilirubin secretion, inherited 
and acquired dysfunction of these proteins can lead to severe cholestatic syndromes and 
conjugated hyperbilirubinemia, respectively[19–21].  
In hormonal cholestasis, in vitro inhibition of BSEP by estrogen and progesterone 
metabolites has been proposed as an underlying pathophysiological mechanism[22]. BSEP 
inhibition by estrogen and progesterone metabolites takes place from the luminal side of the 
bile canaliculus (so-called trans inhibition), which requires previous MRP2-mediated canalicular 
secretion of conjugated metabolites[22,23]. Therefore, MRP2 dysfunction might contribute to this 
form of cholestasis. While sequencing of ABCB11 in unrelated ICP women has not revealed the 
presence of disease-causing BSEP mutations[11], only little attention has so far been paid to the 
possible pathogenic role of functional ABCB11 and ABCC2 polymorphisms. Recent observations 
have suggested that a non-synonymous polymorphism in exon 13 of the ABCB11 gene 
(1331T>C) is overrepresented in drug-induced cholestatic liver injury[24]. The same 
polymorphism has recently been observed more frequently in ICP women compared to healthy 
controls, pointing towards a  possible role of this polymorphism as a susceptibility factor for ICP 
and CIC[25]. Furthermore, two non-synonymous ABCC2 polymorphisms (V1188E and C1515Y) 
showed significant differences in hepatic MRP2 expression levels compared to the wildtype 
sequence, which could be relevant for the extent of BSEP trans inhibition[25].  
The aim of the present study was therefore threefold: (1) to compare allele frequencies 
of the aforementioned ABCB11 and ABCC2 polymorphisms in a prospectively recruited group of 
patients with ICP and CIC; (2) to define the relative risk of the different polymorphisms for the 
development of ICP; and (3) to determine the extent of the increase in serum bile acid levels as 
marker of cholestasis in the presence of the different ABCB11 1331T>C genotypes.  
 
MATERIALS AND METHODS 
Patients and controls 
After approval by the Ethics Committee of the University Hospital of Zurich and written informed 
consent from all participating individuals, blood samples for DNA extraction were obtained from 
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Caucasian patients with ICP or CIC. The total population of analyzed individuals consisted of 
two different groups: 25 patients  (21 ICPnew patients and four CIC patients) were prospectively 
recruited for this study, and a second group of 20 patients (ICPold) had already been described 
in a previous study by Pauli-Magnus and coworkers[11].  
Two hundred and five Caucasian volunteers and patients without cholestasis, as well as 
Caucasian women with uneventful pregnancies (n = 40), served as a control population for 
BSEP and MDR3 genetic variants. These controls have already been described in previous 
studies[11,25,26]. Specifically, pregnant controls were all healthy, as defined by normal serum 
levels of transaminases, bilirubin, γ-GT, alkaline phosphatase (AP) and bile acids. Caucasian 
controls from the study of Pauli-Magnus and coworkers[26] (n = 95) were healthy volunteers 
recruited for participation in phase I studies, with uneventful medical history and normal blood 
biochemistry. Neither of these two control groups took any regular medication. In the case of 
the Caucasian control population of Meier and coworkers[25] (n = 110), most patients suffered 
from extrahepatic malignancies, and cholestatic disease was excluded in all patients. 
Furthermore, none of these patients used medication known to be associated with the 
development of cholestasis.  
For lack of DNA availability, only 110 out of 205 Caucasian controls could be used for 
MRP2 sequencing. For the same reason, a new group of Caucasian women with uneventful 
pregnancies (n = 42) had to be collected for the MRP2 variants. Demographic data and 
pregnancy course of these women did not differ from the previous control group. 
Diagnosis of ICP was based upon: (1) a clinical history of pruritus, which occurred in 
the third trimester of pregnancy; (2) the presence of laboratory abnormalities suggestive of 
ICP: fasting serum bile acid ≥ 1.5 ULN (upper limit of normal) and/ or serum AP levels ≥ 1.5 N 
and/ or alanine aminotransferase (ALT) levels ≥ 1.5 ULN; and (3) spontaneous resolution of 
clinical symptoms and laboratory findings after delivery. Diagnosis of CIC was based upon 
laboratory abnormalities as defined for ICP and the exclusion of preexisting liver disease 
defined by: (1) a negative serology for hepatitis A, B and C; (2) the exclusion of other 
preexisting medical conditions that could explain liver injury, such as congestive heart failure, 
systemic infection, or malignancy; (3) normal liver ultrasound; and (4) a clear causal 
relationship to drug intake. Each case of ICP and CIC was evaluated by at least one obstetrician 
and one hepatologist, as well as by a clinical pharmacologist. 
Full length ABCB4 and ABCB11 sequencing data were already available from the control 
groups, as well as from ICPold patients. To allow detection of additional ABCB4 and ABCB11 
mutations in the new group, complete sequencing of these two genes was also performed in 
the 25 newly recruited patients. Genotyping of ABCC2 included all CIC patients, as well as 17 
out of 21 patients from the ICPnew group and 16 of 21 patients in the ICPold group, which 
yielded a total number of 33 patients for ABCC2 genotyping. In nine patients (four ICPnew and 
five ICPold), no ABCC2 genotyping could be performed for lack of DNA availability. 
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 Sequencing and genotyping 
Isolation of DNA and DNA sequencing was done at Epidauros Biotechnology AG, Bernried, 
Germany. Genomic and cDNA sequences were derived from known sequences (ABCB4: 
AC005068.2 for non-coding exons –3 –1 and coding exons 2 and 3; AC006154.1 for exons 4–
12; AC0005045.2 for exons 13–28; and NM_000443.2 for cDNA; ABCB11: GenBank accession 
number AC008177.3 for promoter and exons 1–21; AC069165.2 for exons 22–28 and 
NM_003742.2 for cDNA).  
ABCB4 and ABCB11. Sequencing of ABCB4 covered ~8 000 bp, including (1) 2 000 bp of the 
upstream promoter region and non-coding exon –3 to 1 and, (2) coding exons 2–28 and 100–
350 bp of the intronic sequence around each exon. For ABCB11, sequencing covered 10 000 bp 
including (1) non-coding exon 1 and 2 400 bp of the upstream promoter region and, (2) coding 
exons 2–28 and 100–350 bp of the intronic sequence around each exon. Primers for genomic 
DNA were designed to span all exons and at least 100 bp of the flanking intronic sequence at 
the 5’ and 3’ end of each exon. The DNA sequence of purified PCR fragments was analyzed on 
an ABI3700 capillary sequencer (ABI, Weiterstadt, Germany) and assembled using the 
phredPhrap, Consed and PolyPhred software (University of Washington). Details regarding the 
primers, optimized PCR conditions and subsequent purification and sequencing of the fragments 
are available at info@epidauros.com.  
ABCC2. Three non-synonymous polymorphisms with a potential impact on MRP2 function and 
expression were chosen for genotyping[25]: 1249G>A variant (V417I, rs2273697), 3563T>A 
(V1188E, rs17222723) and 4544G>A (C1515Y, rs8187710). Genotyping was performed with the 
Custom TaqMan SNP Genotyping Assays procedure (Applied Biosystems, Foster City, CA, USA) 
which contained a sense- and an antisense primer and two probes, labeled with fluorescent 
reporter dyes, either VIC or 6-Fam at the 5’ end and a non-fluorescent quencher at the 3’ end 
to distinguish between alleles 1 and 2, respectively. Primer and probe sequences for individual 
SNPs are given in Table 1. Probe solution (0.625 μL) and 12.5 μL of 2 × Universal PCR Master 
Mix (Applied Biosystems) were brought to 25 μL with 20 ng of genomic DNA. PCR reaction (2 
min at 50°C, followed by 10 min at 95°C and 40 cycles of 15 s at 92°C and 1 min at 60°C). 
Allelic discrimination was processed with an ABI PRISM 7700 Sequence Detector.  
 
Statistical analysis 
Genotype distribution, allelic frequencies and odds ratios (ORs) are given with 95% CI. In 
ABCB11, formal statistical analysis was only performed for the 1331T>C polymorphisms 
(rs2287622), whereas for ABCC2 analysis, it included two highly linked polymorphisms. No 
correction according to Bonferroni was therefore required. Differences investigated in our study 
apply to a proportion of diseased versus non-diseased individuals within the whole population, 
using an unmatched case control design. Response (ICP versus non-ICP) and predictors (T 
versus C) were both binary variables and were therefore best condensed into a 2 × 2 table. 
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Differences in genotype distribution between patients and controls were calculated with the C2 
test, and difference in allelic frequencies between two groups was performed using a 2 × 2 
Fisher exact test. P ≤ 0.05 was considered statistically significant. 
 
RESULTS 
Patient characteristics 
A total of 25 unrelated patients with estrogen-associated intrahepatic cholestasis were 
prospectively enrolled in this study, 21 with ICP and four with oral CIC. Demographic data and 
laboratory findings in ICP patients are given in Table 2. Only two patients showed elevated γ-GT 
levels > 1.5 ULN, while total bile acid levels were elevated in all patients in whom it was 
determined (16 out of 21; range, 1.7–17.3 ULN). Three patients had a previous history of ICP; 
three pregnancies were twin pregnancies, and one patient experienced cholestasis under 
previous oral contraception. 
Characteristics of patients with CIC are given in Table 3. One patient showed elevated 
γ-GT levels. Total bile acid levels were elevated in all three patients in whom it was determined 
(three out of four; range, 1.6–22.3 ULN). Oral contraceptive preparations used in the four 
patients contained comparable amounts of ethinylestradiol (20–35 μg) while the progesterone-
like portion ranged from 50 to 150 μg. All patients had a liver biopsy done for strictly diagnostic 
reasons, which showed intrahepatic cholestasis in three patients. One patient had a previous 
history of ICP. 
 
Sequence analysis  
ABCB4 and ABCB11. Sequence analysis in the 25 newly recruited patients with estrogen-
associated cholestasis revealed no disease-associated non-synonymous mutations in ABCB4 or 
ABCB11. Furthermore, in line with previous findings[11], no ABCB4 polymorphism was found to 
be overrepresented in the ICP and CIC groups compared to pregnant women without 
cholestasis and healthy Caucasian individuals. All of the detected genetic variants in ABCB11 
and ABCB4 were in Hardy Weinberg equilibrium.   
In contrast, the ABCB11 1331T>C → V444A polymorphism was significantly more 
frequent in ICP and CIC patients compared to the two control groups. Specifically, the CC 
genotype was encountered in 57% of all ICP patients (ICPnew, 48% and ICPold, 68%) and 100% 
of CIC patients compared to 20 and 32% in pregnant women without cholestasis and healthy 
Caucasian controls, respectively (Table 4). In line with these findings, the ORs of C versus T 
were 3.0 (1.7–6.4) for all ICP patients (ICPnew + ICPold) versus healthy pregnant control women 
(ICPnew, 2.1; 1–4.7 and ICPold 4.8; 2.2–15.0) (Table 5 and Figure 1). With the exception of this 
polymorphism and two intronic variants that were found to be closely linked to the 1331T>C 
polymorphism in previous studies (intron 13: (+70)C>T and intron 14 (+32)T>C)[26], the allele 
frequency of the remaining common variants in the patients with ICP and CIC was comparable 
 6
to that observed in healthy pregnant and Caucasian controls. Due to the small sample size, no 
significance levels could be calculated for the CIC group. However, all patients in this group 
were homozygous for the C at position 1331, which is highly suggestive of an 
overrepresentation of this allele compared to the control groups.  
 
ABCC2. The 1249G>A polymorphism was not found in our patients. In contrast, 3536T>A and 
4544G>A were strongly linked and distributed similarly in all groups (Table 4). No significant 
difference in the frequency of these two polymorphisms was observed between affected ICP 
and CIC patients and healthy controls. Heterozygous carriers of the 3563A and the 4544A 
alleles were found in 15.2% of ICP patients (ICPnew, 23.5% and ICPold, 3.1%) compared to 11.9 
and 12.7% in pregnant women without cholestasis and healthy Caucasian controls, respectively 
(Table 4). Furthermore, one CIC patient was a heterozygous carrier for the two variant alleles 
at positions 3563 and 4544.  
 
Relation of serum bile acid levels and the ABCB11 1331T>C genotype  
For correlation of bile acid levels with the corresponding genotype at position 1331 of ABCB11, 
ICP and CIC samples were analyzed together. Bile acid levels were available for 16 out of 21 
ICPnew patients, seven out of 20 ICPold  patients, and three out of four CIC patients, which 
yielded a total of 26 samples (CC, 14 patients; CT, 10 patients; and TT, two patients). 
Interindividual variability in serum bile acid levels was high and ranged from 1.7 to 22.3 ULN 
and 1.7 to 17.3 ULN in CC and CT patients, respectively. Serum bile acid levels gradually 
increased from carriers of the TT genotype to carriers of the CC genotype, with medians of 2.3 
ULN (Q1, 2.2; Q3, 2.5), 3.2 ULN (Q1, 2.4; Q3, 6.2) and 4.4 ULN (Q1, 2.2; Q3, 7.8) for TT, TC 
and CC, respectively (Figure 2).  
 
DISCUSSION 
We investigated the risk association between different ABCB11 and ABCC2 polymorphisms in 
ICP and CIC, and correlated different genotypes with serum bile acid levels as a marker of 
cholestasis. In our group of 25 patients with estrogen-associated cholestasis (21 with ICP and 
four with CIC), there was a highly significant association between the presence of the C allele at 
position 1331 of ABCB11 and the presence of cholestasis, which confirms preliminary results 
from another collective of ICP women, in whom such an overrepresentation was first 
observed[11]. While in vitro function of both BSEP variants, as measured by taurocholate 
transport activity, is comparable[24], BSEP expression in healthy liver tissue of Caucasian 
individuals has recently been found to be lower in carriers of the 1331C allele[25]. Such 
differences in hepatic BSEP expression levels might offer one valuable explanation for the 
increased susceptibility to development of cholestasis under specific circumstances, such as 
hormonal challenges. Furthermore, serum bile acids as a marker of in vivo BSEP function was 
influenced by the underlying genotype. Lowest bile acid levels were observed in patients with 
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the TT genotype and highest levels in carriers of the CC genotype. Although the accepted level 
of statistical significance was not reached due to high interindividual variability, this observation 
is in line with the hypothesis that the underlying genotype at position 1331 is a determinant of 
BSEP function, and hence contributes to the individual risk of developing cholestasis.  
The homozygous state for the 1331T>C polymorphism has only recently been observed 
in a very severe case of pregnancy-associated cholestasis with serum bile acid levels >40-fold 
above the ULN. Interestingly, decreased BSEP expression levels were found in a liver biopsy 
obtained from this patient[27]. Although this patient carried an additional ABCB4 mutation, the 
presence of decreased hepatic BSEP expression and highly elevated bile acid levels strongly 
support a BSEP-related mechanism as a predominant pathogenetic factor. The same patient 
also developed severe cholestasis under previous use of oral contraceptives, which supports the 
notion that the same polymorphism also predisposes to oral CIC.  
In our group, seven patients (from ICPold) carried additional ABCB4 mutations, while no 
such mutations were detected in the remaining 35 out of 42 ICP patients (ICPold, 14 and ICPnew, 
21). This finding suggests that the ABCB11 1331T>C polymorphism might independently 
contribute to an individual’s risk for developing cholestasis under certain conditions. On the 
other hand, it can be speculated whether the combination of the 1331T>C polymorphism with 
ABCB4 mutations might be a risk constellation for a severe disease course, as observed by 
Keitel and coworkers[27]. 
In contrast, no association was found between the presence of the non-synonymous 
polymorphisms at positions 1188 and 1515 of MRP2 and the presence of ICP or CIC. A possible 
pathogenic role of these two polymorphisms in ICP and CIC was suspected based upon the 
genotype-dependent alteration in hepatic MRP2 expression levels in healthy human liver tissue 
[25]. Specifically, heterozygous carriers of the glutaminic acid at position 1188 and tyrosine at 
position 1551 showed significantly higher levels of MRP2 in their liver than homozygous carriers 
of valine and cysteine, respectively[25]. As BSEP inhibition by estrogen and progesterone 
metabolites requires prior MRP2-mediated secretion into the bile canaliculus, high MRP2 
expression was suspected as a risk factor for the development of estrogen-dependent 
cholestasis[22]. 
Several conclusions can be drawn from this study. First, our data point toward a 
pathogenic relevance of the ABCB11 1331T>C polymorphism in ICP and CIC. While these types 
of cholestasis are so far mainly attributed to different disease-causing mutations in 
ABCB4[5,11,12], our data support a clear association between the presence of a frequent ABCB11 
polymorphism and ICP. Interestingly, all of the patients with CIC were homozygous carriers of 
the C allele at position 1331. It can be speculated that lower estrogen levels in CIC compared to 
second or third trimester pregnancy require two low-function alleles to result in cholestasis. 
Furthermore, the 1331T>C variant was also found to be associated with other inherited and 
acquired forms of cholestasis, such as benign recurrent intrahepatic cholestasis and drug-
induced cholestasis[24,28,29]. This suggests a role for this polymorphism as a risk factor for 
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different cholestatic conditions, which have so far been regarded as different disease 
entities[20,30]. 
 Second, while γ-GT levels are elevated in ICP patients who carried a disease-causing 
ABCB4 mutation[11], serum bile acid levels are influenced by the BSEP genotype at position 444 
of ABCB11. It can therefore be speculated that these two parameters allow us to clinically 
distinguish between MDR3- and BSEP-related forms of estrogen-related cholestasis, as is 
already done for progressive forms of inherited familial intrahepatic cholestasis[5,21]. From a 
prognostic point of view, this might help to distinguish patients that carry a common 
susceptibility factor from those who carry a disease-causing ABCB4 mutation, which in some 
cases, has been associated with disease progression[7,11,12,31]. Third, although a pathogenic 
involvement of MRP2 in estrogen-induced cholestasis has longely been suspected, common 
ABCC2 polymorphisms have not been associated with the development of cholestasis. We did 
not exclude the presence of disease-associated ABCC2 mutations in our group, but normal 
bilirubin levels in all but one patient suggests no major MRP2 dysfunction, which may result in a 
Dubin Johnson phenotype[32].  
In summary, our data support a role for the ABCB11 1331T>C polymorphism as a 
susceptibility factor for the development of estrogen-induced cholestasis, whereas no such 
association was found for ABCC2. Serum bile acid and γ-GT levels might help to distinguish 
ABCB4 and ABCB11-related forms of ICP and CIC. 
 
COMMENTS 
 
Background 
ICP and oral CIC are two acquired forms of cholestasis, which are observed in 
otherwise healthy young women with a normal medical history. The bile salt export 
pump (BSEP, ABCB11) and the multidrug resistance protein 2 (MRP2, ABCC2) might 
be of pathogenetic importance in both conditions. 
 
Research frontiers 
A genetic predisposition for both types of hormonal cholestasis has been suspected 
based upon the strong regional clustering, the higher prevalence in female family 
members of patients with ICP, and the co-incidence with hereditary cases of progressive 
familial intrahepatic cholestasis. While mutations in the ABCB4 gene that encodes the 
canalicular phospholipid flippase multidrug resistance protein 3 (MDR3) have been 
implicated in the development of ICP and CIC in a subset of affected patients, the role 
of genetic variants in ABCB11 and ABCC2 remains unclear. 
 
Innovations and breakthroughs 
Our data support a role of the ABCB11 1331T>C polymorphism as a susceptibility 
factor for the development of estrogen-induced cholestasis, whereas no such association 
was found for ABCC2. Serum bile acid and γ-GT levels might help to distinguish 
ABCB4- and ABCB11-related forms of ICP and CIC. 
 
Applications 
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While the clinical consequences of such findings are still uncertain at this time, they 
provide important new insights in the role of genetically determined differences in 
canalicular transporter expression and function for the development of estrogen-induced 
cholestasis. In the future, the integration of different factors that predict cholestasis 
might be used to counsel pregnant patients or to avoid certain medications in susceptible 
patients. 
 
Terminology 
ICP: Intrahepatic cholestasis of pregnancy; CIC: contraceptive-induced cholestasis; 
BSEP: Bile Salt Export Pump (ABCB11); MRP2: Multidrug Resistance Protein 2 
(ABCC2); MDR3: Multidrug Resistance Protein 3 (ABCB4). 
 
Peer review 
The study characterized a potential underlying defect in the subgroup of normal γ-GT 
ICP patients and contributes to a clinical risk assessment for the future. This study from 
a group with longstanding experience in transporter genomics is well designed and 
presented in a clearly written manuscript.  
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Table 1 Primers and probes of real-time PCR for allelic discrimination of ABCC2 SNPs in Caucasians 
cDNA 
position1 SNP  Exon 
Amino acid 
change 
Eense-/                                                       
antisense primer Probes 2 
1249 G > A 10 V417I 5’-CCAACTTGGCCAGGAAGGA-3’/  
5’-GGCATCCACAGACATCAGGTT-3’ 
VIC 5’-CTGTTTCTCCAACGGTGTA-3’ 
FAM 5’-ACTGTTTCTCCAATGGTGTA-3’ 
3563 T > A 25 V1188E 5’-GCACCAGCAGCGATTTCTG-3’/ 
5’-AGGTGATCCAGGAAAAGACACATTT-3’ 
VIC 5’-ACACAATGAGGTGAGGAT-3’ 
FAM 5’-ACAATGAGGAGAGGAT-3’ 
4544 G > A 32 C1515Y 5’-GTAATGGTCCTAGACAACGGGAAG-3’/ 
5’-CCAGGGATTTGTAGCAGTTCTTCAG-3’ 
VIC 5’- AGAGTGCGGCAGCC -3’ 
FAM 5’-ATTATAGAGTACGGCAGCC-3’ 
1  cDNA sequence from GenBank accession numbers NM_000392 starting at the ATG; 2   For each SNP two probes were designed and labeled with the fluorescent reporter dyes
1) and FAM (allele 2). SNP: Single nucleotide polymorphism. 
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Table 2 New group of patients with ICP (ICPnew) 
 
  Liver parameters Comments Genotypes of SNPs 
Patient ID 
Age 
(years
) 
ALT 
(ULN) 
AP  
(ULN) 
γ-GT 
(ULN) 
tBili  
(ULN) 
tBA 
(ULN)
No of preg/ 
No ICP  Others 
ABCB11 
1331T>C 
(V444A) 
ABCC2 
3600T>A 
(V1188E) 
ABCC2 
4581G>A 
(C1515Y) 
1 36 0.9 2.3 3.3 0.8 10.7 2/1  CC TA GA 
2 31 1.6 2.5. 0.3 0.8 17.3 3/2  TC TA GA 
3 35 8.9 2.3 1.0 0.5 10 1/1  TC TT GG 
4 29 1.2 3.0 0.6 0.5 7 2/1  CC TT GG 
5 42 11.6 1.4 0.4 0.8 6 1/1  TC TT GG 
6 28 4.8 1.8 0.2 0.8 4.7 2/1 Twins CC TA GA 
7 32 11.9 3.0 1.2 0.9 3.6 nd  CC TT GG 
8 16 5.2 2.0 0.4 nd 3.3 nd  TC TT GG 
9 38 6.2 1.2 1.1 0.4 3 2/1  TC TT GG 
10 23 1.6 1.3 1.3 0.8 2.4 1/1 Twins TC TT GG 
 14 
11 30 0.4 0.9 0.2 0.5 2.4 3/1  TC TT GG 
12 22 0.3 1.8 0.1 0.5 2.1 nd  TC TA GA 
13 32 0.2 0.9 0.7 0.2 2 2/1  TT TT GG 
14 30 0.8 1.2 0.3 0.6 1.7 1/1  CC TT GG 
15 28 7.5 2.3 0.9 0.6 nd nd  TC TT GG 
16 31 0.9 2.1 1.2 0.5 8.1 1/1  CC TT GG 
17 20 3.4 1.1 0.4 0.5 2.6 1/1  TT TT GG 
18 24 7.2 1.3 0.4 0.8 nd 1/1  CC nd nd 
19 31 8.9 1.3 1.2 1.5 nd 2/2  CC nd nd 
20 32 11 2.2 0.4 3.1 nd 3/3 
Pruritus with 
contraceptive
s 
CC nd nd 
21 41 10.9 2.9 5.7 1.2 nd 1/1 Twins CC nd nd 
Summary 
median(Q1,Q3)
31  
(28;32) 
4.8 
(0.9;8.9) 
1.8 
(1.2;2.3)
0.6 
(0.4;1.2)
0.6 
(0.5;0.8)
3.5   
(2.4;7.3
) 
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n/a, Not available; ALT, alanine aminotransferase; tBili, total bilirubin; tBA, total bile acids. 
 
 
Table 3 Characteristics of patients with oral CIC 
   Liver parameters Comments Genotypes of SNPs 
Patien
t ID 
Oral 
contraceptive 
 
Age 
(years
) 
Exposure 
time  
ALT 
(ULN) 
AP 
(ULN)  
γGT 
(ULN)  
tBili  
(ULN)  
tBA 
(ULN)  
Clinical 
features 
 
Histology 
ABCB11 
1331T>C 
(V444A) 
ABCC2 
3600T>A 
(V1188E) 
ABCC2 
4581G>A 
(C1515Y) 
11 30 μg 
ethinylestradiol/   
75 μg 
gestodene 
32 n.d. 4.9 1.7 1 10.9 22.3 Jaundice Intrahepatic 
cholestasis 
CC TT GG 
2 30 μg 
ethinylestradiol/   
150 μg 
levonorgestrel 
15 21 d 1 3 1 4.2 n.d. Jaundice, 
nausea, 
pruritus 
Extensive 
intrahepatic 
cholestasis 
CC TT GG 
3 35 μg 
ethinylestradiol/   
50 μg 
40  2 yr 3.9 2.8 3.6 0.5 1.6 Pruritus Bland CC TT GG 
 16 
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levonorgestrel 
4 35 μg 
ethinylestradio/   
2 mg 
cyproteron 
34  n.d. 1 1.3 n.d. 2.8 1.6 Jaundice Extensive 
canalicular 
cholestasis, 
mild portal 
inflamation 
CC TA GA 
1 Patient exhibited previous episodes of ICP. 
 
Table 4 Genotype distribution of  non-synonymous ABCB11 variant site 1331T>C in patients and controls 
Genotype SNP ICPold  ICPnew ICPtotal Pregnant controls Caucasian controls 
 n (%) 95 % CI n (%) 95 % CI n (%) 95 % CI n (%) 95 % CI n (%) 95 % CI 
ABCB11 1331T>C 
(V444A) 
21 (100)  21 (100)  42 (100)  40(100)  205 (100)  
      TT (VV) - - 2 (9.5) 0.0-22.1 2 (4.8) 0.0-13.9 7 (17.5) 5.7-29.3 38(18.5) 13.2-23.9 
      CC (AA) 14 (67.7) 46.5 -86.8 10 (47.6) 26.3-69.0 24 (57.1) 36.0-78.3 8 (20) 7.6-32.4 66 (32.2) 25.8-38.6 
   TC (VA) 7 (33.3) 13.2-53.5 9 (42.9) 21.7-64.0 16 (38.1) 17.3-58.9 25 (62.5) 47.5-77.5 101 (49.3) 42.4-56.1 
Frequency C allele 35 (83.3) 67.4-99.3 29 (69.0) 49.3-88.8 64 (76.2) 58.0-94.4 41 (51.3) 35.8-66.7 233 (56.8) 50.1-63.6 
Frequency T allele 7 (16.7) 0.7-32.6 13 (31.0) 11.2-50.7 20 (23.8) 5.6-42.0 39 (48.8) 33.3-64.2 177 (43.2) 36.4-50.0) 
ABCC2 3563T>A 
(V1188E) 
16 (100)  17 (100)  33 (100)  42 (100)  110 (100)  
      TT (VV) 15 (93.8) 71.3-98.6 13 (76.5) 52.3-90.4 28 (84.8) 68.9-93.3 37 (88.1) 74.3-96.1 95 (86.4) 68.9-93.3 
      AA (EE) - - - - - - - - 1 (0.9) 0.0-5.0 
   TA (VE) 1 (3.1) 0.0-15.8 4 (23.5) 9.6-47.7 5 (15.2) 6.7-31.1 5 (11.9) 3.9-25.7 14 (12.7) 7.1-20.5 
 18 
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ABCC2 4544G>A 
(C1515Y) 
16 (100)  17 (100)  33 (100)  42 (100)  110 (100)  
      GG (CC) 15 (93.8) 71.3-98.6 13 (76.5) 52.3-90.4 28 (84.8) 68.9-93.3 36 (85.7) 71.4-94.6 95 (86.4) 68.9-93.3 
      AA (YY) - - - - - - - - 1 (0.9) 0.0-5.0 
  GA (CY) 1 (3.1) 0.0-15.8 4 (23.5) 9.6-47.7 5 (15.2) 6.7-31.1 6 (14.3) 5.4-28.6 14 (12.7) 7.1-20.5 
Results are given with 95 percent confidence interval (95% CI). 
 
 
Table 5 1331T>C (V444A): Fisher's exact test and ORs for the presence of homozygous CC variant and the C allele in the different groups 
 CC vs TT C vs T 
 Fisher Odds ratio 95% CI Fisher Odds ratio 95% CI 
ICPold vs Pregnant controls 0.0041 n.d.1 - 0.0004 4.8 2.2 to 15.0 
ICPold vs Caucasian controls  0.0029 n.d. 1 - 0.0005 3.8 1.9 to 11.1 
ICPnew vs Pregnant controls 0.1082 4.4 0.7 to 27.2 0.0441 2.1 1.0 to 4.7 
ICnew vs Caucasian controls 0.1461 2.9 0.6 to 13.8 0.0850 1.7 0.9 to 3.4 
ICPtotal vs Pregnant controls 0.0065 10.5 1.9 to 63.7 0.0007 3.0 1.7 to 6.4 
ICPtotal vs Caucasian controls 0.0025 6.9 1.6 to 32.1 0.0006 2.4 1.5 to 4.5 
1 Could not be determined, as TT = 0.  
 
Figure 1 Allelic frequency of the T allele (white panel) and C allele (black panel) of the ABCB11 1331T>C (1331T>C) polymorphism. 21 ICPnew patients 
(42 alleles); 21 ICPold patients (42 alleles); 42 ICPtotal patients (84 alleles); 20 ICPcontrol patients (40 alleles); 205 Caucasiancontrol patients (410 alleles).  
Allelic frequencies and ORs are given with 95% CI. Groups were compared with Fisher’s exact test. 
 
Figure 2 Bile acid levels in patients harboring different 1331C>T genotypes: TT, two patients; CT, 10 patients; CC, 14 patients. 
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